Treatment of hepatitis B

Journal of Gastroenterology

Volumn 37, Issue 10, 2002, Pages 771-778

  Wai, Chun Tao ^a   Lok, Anna S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Chronic hepatitis B; Interferon alpha; Lamivudine; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; CYTOSINE DERIVATIVE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; STEROID; THYMIDINE DERIVATIVE; THYMOSIN ALPHA1; VIRUS DNA; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ANXIETY DISORDER; AUTOIMMUNE DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; LIVER CIRRHOSIS; LIVER DISEASE; MOOD DISORDER; MYALGIA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REMISSION; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; VIRUS CARRIER; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE;

EID: 0036813577     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350200129     Document Type: Review

References (70)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B 2000, summary of a workshop. Gastroenterology 2001;120: 1828-53.
2. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, editor. Viral hepatitis. New York: Marcel Dekker; 1997. p. 315-30.
3. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Med 1996;2:1104-8.
4. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B after sustained loss of surface antigen. Gastroenterology 1992;103:1649-56.
5. Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000;113:40-55.
6. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3.
7. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999;30: 770-4.
8. Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
9. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1998;8:493-6.
10. Sheen IS, Liaw YF, Tai D, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985;89:732-5.
11. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
12. Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, Bellentani S, Manenti F. Susceptibility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982;II:1243-4.
13. Chevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis. An epidemiologic study. Gastroenterology 1983;85:141-5.
14. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-25.
15. Staeheli P. Interferon-induced proteins and the antiviral state. Adv Virus Res 1990;38:147-200.
16. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-102.
17. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
18. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-8.
19. Lau DY, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis treated with interferon α. Gastroenterology 1997;113:1660-7.
20. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
21. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metaanalysis. Hepatology 1994;20:1390-8.
22. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Inteferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:238-43.
23. Cooksley WG, Pirativsuth T, Wang YJ, Mahachai Y, Chao YC, Tanwandee T, et al. Forty-kda peginterferon alfa-2a (Pegasys®): efficacy and safety results from a phase II, randomised, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B (abstract). Hepatology 2001;34:349.
24. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26:1621-5.
25. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-9.
26. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990;11(Suppl 1):S133-6.
27. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum; response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;14:221-5.
28. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
29. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997;53:74-85.
30. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-71.
31. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
32. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
33. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
34. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
35. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186-94.
36. Song BC, Sub DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
37. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
38. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
39. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61:398-400.
40. Andreone P, Hussain HT, Lok AS, Gramenzi A, Cursaro C, Lorenzini S, et al. Response to extended lamivudine treatment of HBeAg negative chronic hepatitis B (abstract). Hepatology 2001;34:321.
41. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
42. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstract). J Gastroenterol Hepatol 2001;16 (Suppl):60.
43. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91.
44. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients (abstract). Hepatology 1998;28:319.
45. Schiff ER, Heathcote J, Dienstag JL, Hann H-WL, Woessner M, Brown N, et al. Improvements in liver histology and cirrhosis with extended lamivudine therapy (abstract). Hepatology 2000;32:296.
46. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567-72.
47. Schalm SW, Heathcote J, Cianciara J, Ferrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
48. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998;28:388.
49. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial (abstract). Hepatology 2001;34:319.
50. Lau GK, Tsiang M, Hou J, Yuen ST, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study (abstract). Hepatology 2000;32:394.
51. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses lam-resistant hepatitis B virus (HBV) replication: 16 week interim analysis (abstract). J Hepatol 2002;36:6.
52. Low TLK, Goldstein AL. Thymosins: structure, function, and therapeutic applications. Thymus 1984;6:27-43.
53. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001;15:1899-905.
54. Senturk H, Tabak F, Akdogan M, Erdem L, Mert A, Ozaras R, et al. Therapeutic vaccination in chronic hepatitis B. J Gastroenterol Hepatol 2002;17:72-6.
55. Zeuzem S, Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001;52:181-8.
56. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-23.
57. Gilson RJ, Chopra K, Murray-Lyon I, Newell A, Nelson M, Tedder RS, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection (abstract). Hepatology 1996;24:281.
58. One-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103:1635-40.
59. Brosgart C, Fry J, Xiong S, Wulfsohn M, Gibbs C, Toole J, Bischofberger N. Adefovir dipivoxil (ADV) for the treatment of chronic HBV infection (abstract). Antiviral Res 2002;53:151.
60. Perrillo R, Schiff E, Hann HW, Buti M, Strasser S, Watkins KM, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant hepatitis B virus and reduced response to lamivudine. Preliminary 24 weeks results (abstract). Hepatology 2001;34:349.
61. Yang HL, Westland CE, Delaney WE, Ho V, Miller MD, Gibbs CS, et al. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks (abstract). Hepatology 2001;4 (Part 2 Suppl):316.
62. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy; a randomized controlled trial. JAMA 1999; 282:2305-12.
63. Wang C, Corey C, Leung N, Gish RG, Ridney A, Tang L, et al. Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg/DNA +ve chronic hepatitis B (abstract). Hepatology 2001;34:323.
64. Lim SG, Lai CL, Dan YY, Yuen MF, Brown N, Lloyd D, Myers M. Val-LdC: first evidence of efficacy and safety for a new anti-HBV agent (abstract). Gastroenterology 2002;122(4 Suppl):628.
65. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9:208-12.
66. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
67. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-72.
68. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not continue lamivudine therapy after emergence of YMDD mutations (abstract). Gastroenterology 2002;122(4 Suppl):62.
69. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
70. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-9.